Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Intangibles (2021 - 2025)

InMed Pharmaceuticals' Intangibles history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Intangibles fell 9.56% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 9.56%, while the annual FY2025 figure was $1.6 million, 44.64% down from the prior year.
  • Intangibles reached $1.5 million in Q4 2025 per INM's latest filing, down from $2.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $2.9 million in Q4 2023 to a low of $300000.0 in Q2 2023.
  • Average Intangibles over 5 years is $2.0 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Intangibles: plummeted 85.77% in 2023, then soared 875.81% in 2024.
  • A 5-year view of Intangibles shows it stood at $2.4 million in 2021, then decreased by 15.57% to $2.0 million in 2022, then skyrocketed by 44.43% to $2.9 million in 2023, then tumbled by 41.89% to $1.7 million in 2024, then fell by 9.56% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Intangibles are $1.5 million (Q4 2025), $2.9 million (Q3 2025), and $1.6 million (Q2 2025).